MX2022013911A - Peptidos y metodos para el tratamiento de esclerosis multiple. - Google Patents

Peptidos y metodos para el tratamiento de esclerosis multiple.

Info

Publication number
MX2022013911A
MX2022013911A MX2022013911A MX2022013911A MX2022013911A MX 2022013911 A MX2022013911 A MX 2022013911A MX 2022013911 A MX2022013911 A MX 2022013911A MX 2022013911 A MX2022013911 A MX 2022013911A MX 2022013911 A MX2022013911 A MX 2022013911A
Authority
MX
Mexico
Prior art keywords
treatment
peptides
methods
multiple sclerosis
cells
Prior art date
Application number
MX2022013911A
Other languages
English (en)
Inventor
Jean- Marie Saint-Remy
Vincent Carlier
Elst Luc Vander
Milos Erak
Rampelbergh Jean Van
Mechelen Marcelle Van
David Walgraffe
Geoffrey Gloire
Original Assignee
Imcyse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcyse Sa filed Critical Imcyse Sa
Publication of MX2022013911A publication Critical patent/MX2022013911A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)

Abstract

La invención se relaciona con péptidos inmunogénicos derivados de la Glicoproteína de Mielina de Oligodendrocitos (MOG) para uso en el tratamiento de trastornos de desmielinización y la generación de células T CD4+ citolíticas o células NKT contra células presentadoras de antígenos que presentan la secuencia del epítope MOG de tipo salvaje.
MX2022013911A 2020-05-06 2021-05-06 Peptidos y metodos para el tratamiento de esclerosis multiple. MX2022013911A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20173201 2020-05-06
PCT/EP2021/061985 WO2021148683A2 (en) 2020-05-06 2021-05-06 Peptides and methods for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
MX2022013911A true MX2022013911A (es) 2022-11-30

Family

ID=70613608

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013911A MX2022013911A (es) 2020-05-06 2021-05-06 Peptidos y metodos para el tratamiento de esclerosis multiple.

Country Status (16)

Country Link
US (1) US20230340061A1 (es)
EP (1) EP4146676A2 (es)
JP (1) JP2023525084A (es)
KR (1) KR20230006905A (es)
CN (1) CN115702162A (es)
AR (1) AR122023A1 (es)
AU (1) AU2021210629A1 (es)
CA (1) CA3181368A1 (es)
CO (1) CO2022017087A2 (es)
CU (1) CU20220066A7 (es)
IL (1) IL297945A (es)
MX (1) MX2022013911A (es)
PE (1) PE20240491A1 (es)
TW (1) TW202208413A (es)
WO (1) WO2021148683A2 (es)
ZA (1) ZA202212773B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2476435T (pt) 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
EP3915575A1 (en) * 2020-05-29 2021-12-01 Imnate Sarl Vaccine formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2476435T (pt) 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
US20110111395A1 (en) 2008-02-14 2011-05-12 Jean-Marie Saint-Remy Cd4+cells with cytolytic properties
PL2643345T3 (pl) * 2010-11-25 2021-08-16 Imnate Sarl Immunogenne peptydy do zastosowania w zapobieganiu i/lub leczeniu chorób zakaźnych, chorób autoimmunologicznych, odpowiedzi immunologicznych na czynniki allogeniczne, chorób alergicznych, nowotworów, odrzuceniu przeszczepów oraz odpowiedzi immunologicznych skierowanych przeciwko wektorom wirusowym stosowanym w terapii genowej lub szczepieniu genowym
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
BR112018071466A2 (pt) * 2016-04-19 2019-03-19 Imcyse Sa novos peptídeos de ligação a cd1d imunogênicos

Also Published As

Publication number Publication date
AU2021210629A1 (en) 2022-12-08
CU20220066A7 (es) 2023-06-13
TW202208413A (zh) 2022-03-01
IL297945A (en) 2023-01-01
WO2021148683A3 (en) 2021-09-23
AR122023A1 (es) 2022-08-03
US20230340061A1 (en) 2023-10-26
CN115702162A (zh) 2023-02-14
ZA202212773B (en) 2024-04-24
JP2023525084A (ja) 2023-06-14
CO2022017087A2 (es) 2023-02-16
WO2021148683A2 (en) 2021-07-29
CA3181368A1 (en) 2021-07-29
KR20230006905A (ko) 2023-01-11
EP4146676A2 (en) 2023-03-15
PE20240491A1 (es) 2024-03-15

Similar Documents

Publication Publication Date Title
ZA202212773B (en) Peptides and methods for the treatment of multiple sclerosis
MX2021015353A (es) Composiciones y métodos para inmunoterapia de cáncer.
WO2012069568A3 (en) Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
MX2019010459A (es) Vacuna.
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
TR201900852T4 (tr) Nöronal tümörler ve beyin tümörleri dahil olmak üzere çeşitli tümörlere karşı yeni immünoterapi.
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
HK1036805A1 (en) Antigenic complex comprising immunostimulatory peptide, cd4, and chemokine receptor domain for hiv treatment and immune disorders
MX2020011674A (es) Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal.
MX2020010701A (es) Péptidos antigénicos para la prevención y el tratamiento del cáncer.
GB201206070D0 (en) Clostridium difficile antigens
WO2021222285A3 (en) Repeat dosing of hypoimmunogenic cells
MX337756B (es) Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo.
MX2021012004A (es) Composiciones y metodos para preparar composiciones de celulas t y usos de las mismas.
MX2020003129A (es) Composiciones celulares que comprenden linfocitos t específicos para antígenos para una terapia adoptiva.
JP2019517508A (ja) がんの治療における使用のための免疫チェックポイント阻害剤と組み合わされたワクチン
MX2021002449A (es) Vacunas peptidicas.
MX2022006022A (es) Peptido derivado de depdc1 y vacuna que lo contiene.
MX2021015643A (es) Vacuna alogénica contra el virus de inmunodeficiencia humana (vih) basada en linfocitos t para inducir la inmunidad celular y humoral.
MX2021001357A (es) Peptido derivado de cdca1 y vacuna que lo contiene.
JP6490419B2 (ja) 制御性ｔ細胞分化誘導剤
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos
MX2013004417A (es) Peptidos wdhd1 y vacunas que los incluyen.
MX2022000393A (es) Metodo.
WO2023164476A3 (en) Compositions and methods for treating autoimmune disorders